Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Antivir Ther ; 23(6): 495-504, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29714167

RESUMEN

BACKGROUND: Raltegravir (RTG) and dolutegravir (DTG) have different pharmacokinetic patterns in the gastrointestinal tract. To determine if this results in pharmacodynamic differences, we compared HIV RNA, HIV DNA and immunological markers in gut-associated lymphoid tissue (GALT) of HIV-infected participants receiving RTG or DTG with tenofovir+emtricitabine (TDF/FTC). METHODS: GALT specimens from the terminal ileum, splenic flexure and rectum were obtained by colonoscopy at a single time point in 20 adults treated with RTG (n=10) or DTG (n=10) with HIV RNA <50 copies/ml. Flow cytometry, drug concentrations, and HIV RNA and DNA were analysed in tissue. CD4/8+ T-cells were tested for γδ TCR, and markers of T-cell activation and exhaustion. Data are reported as median (Q1-Q3). RESULTS: A total of 15 men and 5 women were enrolled. There was no difference in time since HIV diagnosis for those on RTG (9.5 [4-22] years) and DTG (17 [1-24] years; P=0.6), although time on RTG (5.4 [2.3-6.7] years) was greater than DTG (1.0 [0.1-1.5] years; P<0.001). Concentrations of RTG and DTG in rectal tissue were similar to previous reports: median tissue:plasma ratio was 11.25 for RTG and 0.44 for DTG. RNA:DNA ratios were 1.14 (0.18-5.10) for the RTG group and 0.90 (0.30-18.87) for the DTG group (P=0.95). No differences (P≥0.1) between CD4+ and CD8+ T-cell markers were found. CONCLUSIONS: RTG produced higher tissue exposures than DTG, but no significant differences in GALT HIV RNA, DNA or most immunological markers were observed. ClinicalTrials.gov NCT02218320.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , VIH-1/efectos de los fármacos , Compuestos Heterocíclicos con 3 Anillos/uso terapéutico , Tejido Linfoide/efectos de los fármacos , Raltegravir Potásico/uso terapéutico , Adulto , Recuento de Linfocito CD4 , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/patología , Linfocitos T CD4-Positivos/virología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/patología , Linfocitos T CD8-positivos/virología , Colon Transverso/efectos de los fármacos , Colon Transverso/patología , Colon Transverso/virología , ADN Viral/antagonistas & inhibidores , ADN Viral/genética , ADN Viral/metabolismo , Emtricitabina/uso terapéutico , Femenino , Expresión Génica , Infecciones por VIH/genética , Infecciones por VIH/inmunología , Infecciones por VIH/virología , VIH-1/genética , VIH-1/inmunología , Humanos , Íleon/efectos de los fármacos , Íleon/patología , Íleon/virología , Inmunidad Innata/efectos de los fármacos , Tejido Linfoide/patología , Tejido Linfoide/virología , Masculino , Persona de Mediana Edad , Oxazinas , Piperazinas , Piridonas , ARN Viral/antagonistas & inhibidores , ARN Viral/genética , ARN Viral/metabolismo , Receptores de Antígenos de Linfocitos T gamma-delta/genética , Receptores de Antígenos de Linfocitos T gamma-delta/inmunología , Recto/efectos de los fármacos , Recto/patología , Recto/virología , Tenofovir/uso terapéutico , Resultado del Tratamiento
2.
BMC Gastroenterol ; 17(1): 21, 2017 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-28122499

RESUMEN

BACKGROUND: Uridine (Urd), which has been reported as a major component of RNA, plays an important role in various biological process including neuroprotection, biochemical modulation and glycolysis, although its role in constipation has yet to be established. Therefore, in this study, we investigated the laxative effects of Urd on chronic constipation. METHODS: The constipation phenotypes and their related mechanisms were investigated in the transverse colons of SD rats with loperamide (Lop)-induced constipation after treatment with 100 mg/kg of Urd. RESULTS: The number, weight and water contents of stools were significantly higher in the Lop + Urd treated group than the Lop + Vehicle treated group, while food intake and water consumption of the same group were maintained at a constant level. The thickness of the mucosa layer, muscle and flat luminal surface, as well as the number of goblet cells, paneth cells and lipid droplets were enhanced in the Lop + Urd treated group. Furthermore, the expression of the muscarinic acetylcholine receptors M2 and M3 (mAChR M2 and M3) at the transcriptional and translational level was recovered in the Lop + Urd treated group, while some markers such as Gα and inositol triphosphate (IP3) in their downstream signaling pathway were completely recovered by Urd treatment. Moreover, the ability for mucin secretion and the expression of membrane water channel (aquaporine 8, AQP8) were increased significantly in the Lop + Urd treated group compared with Lop + Vehicle treated group. Finally, the activity of Urd was confirmed in primary smooth muscle of rat intestine cells (pRISMC) based on Gα expression and IP3 concentration. CONCLUSIONS: The results of the present study provide the first strong evidence that Urd can be considered an important candidate for improving chronic constipation induced by Lop treatment in animal models.


Asunto(s)
Estreñimiento/tratamiento farmacológico , Estreñimiento/metabolismo , Laxativos/uso terapéutico , Mucinas/metabolismo , Receptor Muscarínico M2/metabolismo , Receptor Muscarínico M3/metabolismo , Uridina/uso terapéutico , Animales , Colon Transverso/efectos de los fármacos , Colon Transverso/patología , Colon Transverso/ultraestructura , Modelos Animales de Enfermedad , Conducta Alimentaria/efectos de los fármacos , Fosfatos de Inositol/metabolismo , Mucosa Intestinal/metabolismo , Mucinas/efectos de los fármacos , Músculo Liso/metabolismo , Ratas Sprague-Dawley , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M3/efectos de los fármacos , Transducción de Señal , Uridina/metabolismo , Uridina/farmacología
3.
Mol Med Rep ; 15(1): 431-441, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27922695

RESUMEN

The laxative effects of aqueous extract of Liriope platyphylla (AEtLP) on loperamide (Lop)­induced constipation have been reported; however, the key compounds and the mechanism underlying these effects remain unclear. Therefore, the laxative effects of five candidates derived from L. platyphylla: Diosgenin (DG), 5-hydroxymethylfurfural (5-HMF), adenosine (AD), hydroxypropyl cellulose (HPC) and uridine (UD) were investigated by examining the alteration of G protein α (Gα) expression, protein kinase C (PKC) phosphorylation and inositol triphosphate (IP3) concentration levels in the 5-hydroxytryptamine (5­HT; serotonin) receptor signaling pathway. Primary rat intestine smooth muscle cells (pRISMCs), intestinal epithelial cells (IEC)­18 and B35 cells were cotreated with Lop and the five compounds in order to screen the candidates. AEtLP, prucalopride (PCP) and bisacodyl (BS) served as positive controls. In pRISMCs, Gα expression levels were recovered in the majority of candidate­treated groups, whereas PKC phosphorylation recovery was observed only in the DG, 5­HMF and AD treatment groups. In IEC­18 cells, the AD treatment group mimicked the effects of PCP on PKC phosphorylation levels, whereas the DG, 5­HMF, HPC and UD treatment groups mimicked the effects of AEtLP and BS. In B35 cells, a greater upregulation of PKC phosphorylation levels were observed in the UD treatment group compared with the PCP and BS treatment groups, whereas DG, 5­HMF and AD treatment reduced the PKC phosphorylation levels to a greater extent than AEtLP treatment. However, effects similar to AEtLP, PCP and BS on Gα expression levels were not detected in any treatment groups in IEC­18 and B35 cells. Furthermore, the level of IP3 was enhanced only in pRISMCs, in which all five candidates were effective, while the greatest concentration was observed in the UD treatment group. In conclusion, the results of the present study suggest that UD may be considered the compound with the greatest laxative activity, which may regulate the 5­HT receptor signaling pathway.


Asunto(s)
Colon Transverso/efectos de los fármacos , Laxativos/química , Laxativos/farmacología , Liriope (Planta)/química , Extractos Vegetales/química , Extractos Vegetales/farmacología , Receptores de Serotonina/metabolismo , Animales , Células Cultivadas , Colon Transverso/citología , Colon Transverso/metabolismo , Estreñimiento/tratamiento farmacológico , Estreñimiento/metabolismo , Femenino , Laxativos/aislamiento & purificación , Extractos Vegetales/aislamiento & purificación , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos
4.
PLoS Pathog ; 10(6): e1004198, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24968145

RESUMEN

Effective antiretroviral therapy (ART) dramatically reduces AIDS-related complications, yet the life expectancy of long-term ART-treated HIV-infected patients remains shortened compared to that of uninfected controls, due to increased risk of non-AIDS related morbidities. Many propose that these complications result from translocated microbial products from the gut that stimulate systemic inflammation--a consequence of increased intestinal paracellular permeability that persists in this population. Concurrent intestinal immunodeficiency and structural barrier deterioration are postulated to drive microbial translocation, and direct evidence of intestinal epithelial breakdown has been reported in untreated pathogenic SIV infection of rhesus macaques. To assess and characterize the extent of epithelial cell damage in virally-suppressed HIV-infected patients, we analyzed intestinal biopsy tissues for changes in the epithelium at the cellular and molecular level. The intestinal epithelium in the HIV gut is grossly intact, exhibiting no decreases in the relative abundance and packing of intestinal epithelial cells. We found no evidence for structural and subcellular localization changes in intestinal epithelial tight junctions (TJ), but observed significant decreases in the colonic, but not terminal ileal, transcript levels of TJ components in the HIV+ cohort. This result is confirmed by a reduction in TJ proteins in the descending colon of HIV+ patients. In the HIV+ cohort, colonic TJ transcript levels progressively decreased along the proximal-to-distal axis. In contrast, expression levels of the same TJ transcripts stayed unchanged, or progressively increased, from the proximal-to-distal gut in the healthy controls. Non-TJ intestinal epithelial cell-specific mRNAs reveal differing patterns of HIV-associated transcriptional alteration, arguing for an overall change in intestinal epithelial transcriptional regulation in the HIV colon. These findings suggest that persistent intestinal epithelial dysregulation involving a reduction in TJ expression is a mechanism driving increases in colonic permeability and microbial translocation in the ART-treated HIV-infected patient, and a possible immunopathogenic factor for non-AIDS related complications.


Asunto(s)
Fármacos Anti-VIH/efectos adversos , Colon/efectos de los fármacos , Regulación hacia Abajo/efectos de los fármacos , Infecciones por VIH/tratamiento farmacológico , Mucosa Intestinal/efectos de los fármacos , Proteínas de Uniones Estrechas/antagonistas & inhibidores , Uniones Estrechas/efectos de los fármacos , Centros Médicos Académicos , Fármacos Anti-VIH/uso terapéutico , Estudios de Cohortes , Colon/metabolismo , Colon/patología , Colon/virología , Colon Ascendente/efectos de los fármacos , Colon Ascendente/metabolismo , Colon Ascendente/patología , Colon Ascendente/virología , Colon Descendente/efectos de los fármacos , Colon Descendente/metabolismo , Colon Descendente/patología , Colon Descendente/virología , Colon Transverso/efectos de los fármacos , Colon Transverso/metabolismo , Colon Transverso/patología , Colon Transverso/virología , Femenino , Infecciones por VIH/metabolismo , Infecciones por VIH/patología , Infecciones por VIH/virología , Humanos , Íleon/efectos de los fármacos , Íleon/metabolismo , Íleon/patología , Íleon/virología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Mucosa Intestinal/virología , Masculino , Persona de Mediana Edad , Ohio , Especificidad de Órganos , Permeabilidad/efectos de los fármacos , Proteínas de Uniones Estrechas/genética , Proteínas de Uniones Estrechas/metabolismo , Uniones Estrechas/metabolismo , Uniones Estrechas/patología , Uniones Estrechas/virología
5.
BMC Complement Altern Med ; 13: 333, 2013 Nov 26.
Artículo en Inglés | MEDLINE | ID: mdl-24274470

RESUMEN

BACKGROUND: Liriope platyphylla has long been reported as a therapeutic drug for treatment of various human chronic diseases including inflammation, diabetes, neurodegenerative disorders, obesity, and atopic dermatitis. To investigate the laxative effects of L. platyphylla, alterations in excretion parameters, histological structure, mucin secretion, and related protein levels were investigated in rats with loperamide (Lop)-induced constipation after treatment with aqueous extract of L. platyphylla (AEtLP). METHODS: Alterations on constipation phenotypes were measured in rats with Lop-induced constipation after treatment with AEtLP using excretion parameter analysis, histological analysis, RT-PCR, western blot and transmission electron microscope (TEM) analysis. RESULTS: The amounts of stool and urine excretion were significantly higher in the Lop + AEtLP-treated group than in the Lop + vehicle-treated group, whereas food intake and water consumption were maintained at constant levels. AEtLP treatment also induced an increase in villus length, crypt layer, and muscle thickness in the constipation model. Total mucin secretion was higher in the Lop + AEtLP-treated group than in the Lop + vehicle-treated group, although mucin secretion per crypt was very similar among all groups. Furthermore, RT-PCR and western blot revealed a dramatic reduction of key factors level on the muscarinic acetylcholine receptors (mAChRs) signaling pathway in the Lop + AEtLP-treated group relative to the Lop + vehicle-treated group. Especially, the accumulation of lipid droplets in enterocytes of crypts following Lop treatment was improved to the level of the No-treated group in response to AEtLP treatment. CONCLUSION: These results suggest that AEtLP improves constipation induced by Lop treatment through an increase in crypt layer and stimulation of lipid droplet secretions. These data are the first to show that the laxative effects of AEtLP are closely related to the down-regulation of mAchRs and their downstream signals.


Asunto(s)
Estreñimiento/tratamiento farmacológico , Laxativos/farmacología , Liriope (Planta)/química , Extractos Vegetales/farmacología , Análisis de Varianza , Animales , Peso Corporal/efectos de los fármacos , Colon Transverso/efectos de los fármacos , Colon Transverso/patología , Colon Transverso/ultraestructura , Estreñimiento/inducido químicamente , Defecación/efectos de los fármacos , Loperamida , Masculino , Mucinas/metabolismo , Ratas , Receptores Muscarínicos/metabolismo , Transducción de Señal/efectos de los fármacos , Micción/efectos de los fármacos
6.
Am J Physiol Endocrinol Metab ; 303(9): E1142-50, 2012 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-22932783

RESUMEN

The hormone relaxin exerts a variety of functions on the smooth muscle of reproductive and nonreproductive organs, most of which occur through a nitric oxide (NO)-mediated mechanism. In the stomach and ileum, relaxin causes muscle relaxation by modulating the activity and expression of different nitric oxide synthase (NOS) isoforms region-dependently. Nothing is known on the effects of relaxin in the colon, the gut region expressing the highest number of neuronal (n) NOSß-immunoreactive neurons and mainly involved in motor symptoms of pregnancy and menstrual cycle. Therefore, we studied the effects of relaxin exposure in the mouse proximal colon in vitro evaluating muscle mechanical activity and NOS isoform expression. The functional experiments showed that relaxin decreases muscle tone and increases amplitude of spontaneous contractions; the immunohistochemical results showed that relaxin increases nNOSß and endothelial (e) NOS expression in the neurons and decreases nNOSα and eNOS expression in the smooth muscle cells (SMC). We hypothesized that, in the colon, relaxin primarily increases the activity and expression of nNOSß and eNOS in the neurons, causing a reduction of the muscle tone. The downregulation of nNOSα and eNOS expression in the SMC associated with increased muscle contractility could be the consequence of continuous exposue of these cells to the NO of neuronal origin. These findings may help to better understand the physiology of NO in the gastrointestinal tract and the role that the "relaxin-NO" system plays in motor disorders such as functional bowel disease.


Asunto(s)
Colon/metabolismo , Contracción Muscular , Músculo Liso/metabolismo , Neuronas/metabolismo , Óxido Nítrico Sintasa de Tipo III/metabolismo , Óxido Nítrico Sintasa de Tipo I/metabolismo , Relaxina/metabolismo , Anestésicos Locales/farmacología , Animales , Colon/irrigación sanguínea , Colon/citología , Colon/inervación , Colon Ascendente/citología , Colon Ascendente/efectos de los fármacos , Colon Ascendente/inervación , Colon Ascendente/metabolismo , Colon Transverso/citología , Colon Transverso/efectos de los fármacos , Colon Transverso/inervación , Colon Transverso/metabolismo , Inhibidores Enzimáticos/farmacología , Femenino , Guanilato Ciclasa/antagonistas & inhibidores , Técnicas In Vitro , Células Intersticiales de Cajal/citología , Células Intersticiales de Cajal/efectos de los fármacos , Células Intersticiales de Cajal/metabolismo , Fenómenos Mecánicos , Ratones , Ratones Endogámicos , Contracción Muscular/efectos de los fármacos , Músculo Liso/irrigación sanguínea , Músculo Liso/citología , Músculo Liso/inervación , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/metabolismo , Neuronas/citología , Neuronas/efectos de los fármacos , Donantes de Óxido Nítrico/farmacología , Óxido Nítrico Sintasa de Tipo I/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo III/antagonistas & inhibidores , Concentración Osmolar , Plexo Submucoso/citología , Plexo Submucoso/efectos de los fármacos , Plexo Submucoso/metabolismo
7.
Tumori ; 97(6): 794-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22322848

RESUMEN

There are no effective conventional systemic cytotoxic therapies for patients with unresectable or advanced hepatocellar carcinoma (HCC). Sorafenib, an oral multi-targeted tyrosine kinase inhibitor, was recently approved for the treatment of patients with HCC. Sorafenib is generally well tolerated and has an acceptable toxicity profile.Gastrointestinal perforation is a rare adverse event. We present a case of transverse colon perforation during sorafenib therapy for advanced HCC. A 68-year-old woman with advanced HCC was treated with sorafenib. Eight weeks later the patient presented with the sudden onset of sharp abdominal pain. Emergency surgery was performed for panperitonitis and a perforation involving the transverse colon.


Asunto(s)
Antineoplásicos/efectos adversos , Bencenosulfonatos/efectos adversos , Carcinoma Hepatocelular/tratamiento farmacológico , Enfermedades del Colon/inducido químicamente , Enfermedades del Colon/diagnóstico , Perforación Intestinal/inducido químicamente , Perforación Intestinal/diagnóstico , Neoplasias Hepáticas/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/efectos adversos , Piridinas/efectos adversos , Dolor Abdominal/etiología , Anciano , Antineoplásicos/administración & dosificación , Bencenosulfonatos/administración & dosificación , Colon Transverso/irrigación sanguínea , Colon Transverso/efectos de los fármacos , Enfermedades del Colon/complicaciones , Enfermedades del Colon/patología , Enfermedades del Colon/cirugía , Femenino , Humanos , Perforación Intestinal/complicaciones , Perforación Intestinal/patología , Perforación Intestinal/cirugía , Isquemia/inducido químicamente , Isquemia/complicaciones , Niacinamida/análogos & derivados , Peritonitis/complicaciones , Peritonitis/etiología , Peritonitis/cirugía , Compuestos de Fenilurea , Inhibidores de Proteínas Quinasas/administración & dosificación , Piridinas/administración & dosificación , Sorafenib , Tomografía Computarizada por Rayos X
8.
J Pharmacol Sci ; 109(1): 128-38, 2009 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19129681

RESUMEN

Nicotine has been shown to reduce both tone and muscular activity in the human colon by releasing nitric oxide (NO) from nerves. To our knowledge, however, the effect of nicotine on mouse colon has not been elucidated, and the response in tissue from ulcerative colitis (UC) has not been investigated. We examined nicotine-induced responses in colon from control mice and mice with dextran sodium sulfate (DSS)-induced UC. In controls, bath application of nicotine caused a transient relaxation in longitudinal preparations from the transverse and distal colons but not from the rectum. The response was observed in the presence of bethanechol, abolished by treatment with tetrodotoxin and hexamethonium, and mediated partially (>50%) by the NO pathway. In longitudinal preparations of the distal colon from DSS-treated mice, spontaneous contractions decreased markedly, and nicotine caused contraction without relaxation in half of the preparations tested. Nicotine-induced relaxation in the presence of bethanechol was significantly decreased in the DSS-treated distal colon without changing bethanechol-induced contractions. These data suggest that 1) responses to nicotine differ dependent on colon regions, 2) DSS treatment predominantly caused nicotine-sensitive neurogenic changes in distal colon, and 3) DSS treatment may reverse the direction of nicotine-evoked responses in the colon, in mice.


Asunto(s)
Colitis Ulcerosa/fisiopatología , Colon/efectos de los fármacos , Relajación Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Nicotina/farmacología , Animales , Atropina/farmacología , Betanecol/farmacología , Colitis Ulcerosa/inducido químicamente , Colon/inervación , Colon/fisiología , Colon Descendente/efectos de los fármacos , Colon Descendente/inervación , Colon Descendente/fisiología , Colon Transverso/efectos de los fármacos , Colon Transverso/inervación , Colon Transverso/fisiología , Sulfato de Dextran , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Inhibidores Enzimáticos/farmacología , Estimulantes Ganglionares/farmacología , Hexametonio/farmacología , Técnicas In Vitro , Indometacina/farmacología , Masculino , Ratones , Relajación Muscular/fisiología , Músculo Liso/inervación , Músculo Liso/fisiología , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Parasimpaticomiméticos/farmacología , Tetrodotoxina/farmacología
9.
Methods Find Exp Clin Pharmacol ; 28(8): 499-505, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17136228

RESUMEN

The pharmacological action of vitamin E on the mechanical activity of isolated guinea pig colonic smooth muscle was examined in normoxic and hypoxic conditions. In hypoxia, but not normoxia, alpha-tocopherol (1-160 microM) evoked rapid concentration-dependent contractions from the colon. This was also seen with other members of the vitamin E family, and potency measurements gave EC(50) values (microM) of 10.6 +/- 0.9 for D-alpha-tocopherol, 6.0 +/- 1.2 for D-beta-tocopherol, 7.5 +/- 0.7 for D-gamma-tocopherol, and 6.1 +/- 1.5 for D-delta-tocopherol. This order of potency for the components of the vitamin differs from previously studied bioassay systems and from their antioxidant activity. A range of potent natural and synthetic antioxidants was not active in this system. Compounds with structural similarities to the side chain of vitamin E produced similar stimulatory responses and some, like phytol, were more potent than the vitamin (EC(50): 1.0 +/- 0.2 microM), whereas ring structures related to the vitamin, like Trolox C, antagonized the stimulant responses in a concentration-dependent manner. Therefore, this model system measures, directly, vitamin E-induced responses through a mechanism that does not appear to be related to the known antioxidant capacity of these agents.


Asunto(s)
Antioxidantes/farmacología , Contracción Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , alfa-Tocoferol/farmacología , Animales , Antioxidantes/química , Ácido Ascórbico/farmacología , Cromanos/farmacología , Colon Transverso/efectos de los fármacos , Colon Transverso/fisiología , Relación Dosis-Respuesta a Droga , Femenino , Cobayas , Hipoxia , Técnicas In Vitro , Contracción Isométrica/efectos de los fármacos , Masculino , Metacrilatos/farmacología , Músculo Liso/fisiología , Fitol/farmacología , Pirogalol/farmacología , Relación Estructura-Actividad Cuantitativa , Estereoisomerismo , Temperatura , Terpenos/química , Terpenos/farmacología , alfa-Tocoferol/química
10.
Int Immunopharmacol ; 3(13-14): 1731-41, 2003 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-14636824

RESUMEN

In this study, we have evaluated the efficacy of dosmalfate, a new flavonoid derivative compound, for the prevention and treatment of experimental colitis. To induce colitis, BALB/c mice received 5% dextran sulphate sodium (DSS) in their drinking water continuously for 7 days. Colitis was quantified by a clinical damage score, colon length, weight loss, stool consistency and rectal bleeding. Inflammatory response was assessed by neutrophil infiltration, determined by histology and myeloperoxidase (MPO) activity. Interleukin (IL)-1 beta, prostaglandins (PG)E(2) and (PG)D(2) concentrations in colonic tissue, histological and histochemical analysis of the lesions were also measured. Dosmalfate (400-800 mg/kg body weight, p.o.) ameliorated severe colitis reduced the degree of inflammation through reduction of neutrophil infiltration and IL-1 beta levels. (PG)E(2) and (PG)D(2) synthesis were significantly reduced in colitis control group and treatment with dosmalfate abolished the decrease in PG synthesis in colon mucosa. We conclude that dosmalfate is protective in acute DSS-induced colitis. The beneficial effects seem to be related to a decrease of neutrophil infiltration, absence of up-regulation of IL-1 beta and increase of PG production in colon mucosa.


Asunto(s)
Colitis Ulcerosa/inducido químicamente , Sulfato de Dextran/efectos adversos , Sulfato de Dextran/antagonistas & inhibidores , Diosmina/análogos & derivados , Diosmina/uso terapéutico , Administración Oral , Animales , Colitis Ulcerosa/tratamiento farmacológico , Colon Descendente/efectos de los fármacos , Colon Descendente/lesiones , Colon Descendente/ultraestructura , Colon Transverso/efectos de los fármacos , Colon Transverso/lesiones , Colon Transverso/ultraestructura , Sulfato de Dextran/administración & dosificación , Dinoprostona/biosíntesis , Diosmina/administración & dosificación , Diosmina/farmacocinética , Modelos Animales de Enfermedad , Ingestión de Líquidos , Flavonoides/administración & dosificación , Flavonoides/química , Flavonoides/farmacocinética , Interleucina-1/biosíntesis , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/enzimología , Mucosa Intestinal/lesiones , Masculino , Ratones , Ratones Endogámicos BALB C , Infiltración Neutrófila/efectos de los fármacos , Peroxidasa/metabolismo , Prostaglandina D2/biosíntesis , Factores de Tiempo , Agua
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA